BidaskClub upgraded shares of IDEXX Laboratories (NASDAQ:IDXX) from a hold rating to a buy rating in a research note issued to investors on Tuesday.

Several other analysts have also recently commented on the stock. Piper Jaffray Companies assumed coverage on shares of IDEXX Laboratories in a report on Tuesday. They set an overweight rating and a $200.00 price target for the company. Aegis restated a sell rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a hold rating to a buy rating and set a $184.00 price target for the company in a report on Tuesday, October 24th. Stifel Nicolaus restated a buy rating and set a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Canaccord Genuity restated a buy rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $177.43.

IDEXX Laboratories (IDXX) traded up $1.63 during trading on Tuesday, hitting $180.63. 602,985 shares of the stock traded hands, compared to its average volume of 471,386. The stock has a market capitalization of $15,900.00, a P/E ratio of 58.65, a P/E/G ratio of 2.41 and a beta of 0.42. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories has a 1-year low of $116.54 and a 1-year high of $180.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million during the quarter, compared to analysts’ expectations of $492.94 million. The business’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $0.62 earnings per share. research analysts predict that IDEXX Laboratories will post 3.24 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total value of $2,767,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,678,098.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the sale, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. D.A. Davidson & CO. lifted its stake in IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after acquiring an additional 385 shares during the last quarter. Sun Life Financial INC lifted its stake in IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after acquiring an additional 636 shares during the last quarter. BB&T Investment Services Inc. acquired a new stake in IDEXX Laboratories in the second quarter valued at approximately $104,000. Zions Bancorporation acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $162,000. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 86.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/20/idexx-laboratories-idxx-raised-to-buy-at-bidaskclub.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.